Ask AI
ProCE Banner Activity

FAQs: Immunotherapy for Nonmelanoma Skin Cancer

Clinical Thought

The personalized care of patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) requires assessment of tumor risk, cumulative surgical morbidity, comorbidities, and patient preferences when considering immunotherapy as an alternative or adjunct to surgical therapy. In this commentary, an expert addresses questions about multidisciplinary treatment selection, clinical and histopathologic response assessment, considerations for treatment duration and discontinuation, management of immune-related adverse events, and patient-centered considerations related to treatment burden, quality of life, and cosmetic outcomes in BCC and CSCC.

Released: November 13, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity is intended for oncologists, dermatologists, advanced practice providers, nurses, pharmacists, and other HCPs who care for patients with basal cell carcinoma and cutaneous squamous cell carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients with BCC and CSCC on the risks and benefits of immune checkpoint inhibitor therapy

  • Integrate immune checkpoint inhibitors into treatment plans for appropriate patients with BCC and CSCC, considering clinical data and expert recommendations along with patient goals and perspectives

  • Evaluate the potential clinical impact of novel intralesional and perioperative immune checkpoint inhibitor therapies under investigation for patients with BCC and CSCC

  • Manage immune-related adverse events promptly in patients with BCC and CSCC who are receiving immune checkpoint inhibitor therapy

Financial Disclosures

Primary Author

Kevin Emerick, MD: consultant/advisor/speaker: Regeneron; researcher: Haystack/Quest Diagnostic.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.